Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

The histone methyltransferase SETD8, which methylates the lysine 20 of histone H4 (H4K20), is reportedly involved in human carcinogenesis along with nonhistone proteins such as p53. However, its expression profiles and functions in the context of high-grade serous ovarian carcinoma (HGSOC) are still...

Full description

Bibliographic Details
Main Authors: Miku Wada, Asako Kukita, Kenbun Sone, Ryuji Hamamoto, Syuzo Kaneko, Masaaki Komatsu, Yu Takahashi, Futaba Inoue, Machiko Kojima, Harunori Honjoh, Ayumi Taguchi, Tomoko Kashiyama, Yuichiro Miyamoto, Michihiro Tanikawa, Tetsushi Tsuruga, Mayuyo Mori-Uchino, Osamu Wada-Hiraike, Yutaka Osuga, Tomoyuki Fujii
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Biomolecules
Subjects:
epigenetic modifier
histone methyltransferase
SETD8
high-grade serous ovarian cancer
UNC0379
H4K20 monomethylation
Online Access:https://www.mdpi.com/2218-273X/10/12/1686

Internet

https://www.mdpi.com/2218-273X/10/12/1686

Similar Items